



## Targeting MHC Regulation Using Polycyclic Polyprenylated Acylphloroglucinols Isolated from *Garcinia bancana*

Chloé Coste, Nathalie Gérard, Chau-Phi Dinh, Antoine Bruguière, Caroline Rouger, Sow Tein Leong, Khalijah Awang, Pascal Richomme, Séverine Derbré,  
Béatrice Charreau

### ► To cite this version:

Chloé Coste, Nathalie Gérard, Chau-Phi Dinh, Antoine Bruguière, Caroline Rouger, et al.. Targeting MHC Regulation Using Polycyclic Polyprenylated Acylphloroglucinols Isolated from *Garcinia bancana*. *Biomolecules*, 2020, 10 (1266), pp.1-17. 10.3390/biom10091266 . hal-02930094

**HAL Id: hal-02930094**

**<https://univ-angers.hal.science/hal-02930094>**

Submitted on 4 Sep 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

## Article

# Targeting MHC Regulation Using Polycyclic Polyprenylated Acylphloroglucinols Isolated from *Garcinia bancana*

Chloé Coste <sup>1,2</sup>, Nathalie Gérard <sup>1</sup> , Chau Phi Dinh <sup>2</sup> , Antoine Bruguière <sup>2</sup>,  
Caroline Rouger <sup>2,†</sup> , Sow Tein Leong <sup>3</sup> , Khalijah Awang <sup>3</sup>, Pascal Richomme <sup>2</sup>,  
Séverine Derbré <sup>2,\*‡</sup>  and Béatrice Charreau <sup>1,\*‡</sup> 

<sup>1</sup> Université de Nantes, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France; chloe.coste@agrocampus-ouest.fr (C.C.); Nathalie.Gerard@univ-nantes.fr (N.G.)

<sup>2</sup> SONAS, EA921, University of Angers, SFR QUASAV, Faculty of Health Sciences, Department of Pharmacy, CEDEX 01, 49045 Angers, France; chauphi.dinh@univ-angers.fr (C.P.D.); antoine.bruguiere@outlook.com (A.B.); caroline.rouger@u-bordeaux.fr (C.R.); pascal.richomme@univ-angers.fr (P.R.)

<sup>3</sup> Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia; sowtein@hotmail.com (S.T.L.); khalijah@um.edu.my (K.A.)

\* Correspondence: severine.derbre@univ-angers.fr (S.D.); Beatrice.Charreau@univ-nantes.fr (B.C.); Tel.: +33-249-180-440 (S.D.); +33-240-087-416 (B.C.); Fax: +33-240-087-411 (B.C.)

† Current address: Unité de Recherche CEnologie, EA 4577, USC 1366 INRAE, ISVV, Université de Bordeaux, 33882 Villenave d'Ornon, France.

‡ Both last authors contributed equally to the work as senior authors.

Received: 4 August 2020; Accepted: 28 August 2020; Published: 2 September 2020



**Abstract:** Modulation of major histocompatibility complex (MHC) expression using drugs has been proposed to control immunity. Phytochemical investigations on *Garcinia* species have allowed the isolation of bioactive compounds such as polycyclic polyprenylated acylphloroglucinols (PPAPs). PPAPs such as guttiferone J (1), display anti-inflammatory and immunoregulatory activities while garcinol (4) is a histone acetyltransferases (HAT) p300 inhibitor. This study reports on the isolation, identification and biological characterization of two other PPAPs, i.e., xanthochymol (2) and guttiferone F (3) from *Garcinia bancana*, sharing structural analogy with guttiferone J (1) and garcinol (4). We show that PPAPs 1–4 efficiently downregulated the expression of several MHC molecules (HLA-class I, -class II, MICA/B and HLA-E) at the surface of human primary endothelial cells upon inflammation. Mechanistically, PPAPs 1–4 reduce MHC proteins by decreasing the expression and phosphorylation of the transcription factor STAT1 involved in MHC upregulation mediated by IFN- $\gamma$ . Loss of STAT1 activity results from inhibition of HAT CBP/p300 activity reflected by a hypoacetylation state. The binding interactions to p300 were confirmed through molecular docking. Loss of STAT1 impairs the expression of CIITA and GATA2 but also TAP1 and Tapasin required for peptide loading and transport of MHC. Overall, we identified new PPAPs issued from *Garcinia bancana* with potential immunoregulatory properties.

**Keywords:** endothelium; Clusiaceae; *Garcinia bancana*; guttiferone F; guttiferone J; major histocompatibility complex; HLA-E; polycyclic polyprenylated acylphloroglucinols; xanthochymol; histone acetyltransferase

## 1. Introduction

Major histocompatibility complex (MHC) molecules, also known as histocompatibility antigens or human leucocytes antigens (HLA) in humans, are highly polymorphic glycoproteins encoded by MHC class I and MHC class II genes. Classical MHC molecules are triggers of innate and adaptive immune responses against pathogens and tumors [1]. They are involved in the presentation of peptide antigens to T cells. In humans, there are three class I genes, called HLA-A, -B and -C, and three of MHC class II genes, called HLA-DR, -DP and -DQ. MHC class II molecules provide antigen presentation to induce antigen-specific CD4 T cells while MHC class I molecules trigger the activation of CD8 T cells to generate cytotoxic T lymphocytes and natural killer (NK) cells to eradicate infected or transformed cells [2]. As a part of the immune response, to enhance lymphocyte activation, expression of MHC molecules is upregulated by interferon- $\gamma$  (IFN $\gamma$ ), which transduces signal via the Janus tyrosine kinase (Jak)1 and the latent cytosolic factor, signal transducer and activator of transcription (STAT)1. MHC class II transactivator (CIITA) is a global regulator involved in basal and IFN $\gamma$  mediated MHC transcription in two distinct ways: as a transcriptional activator that nucleate an enhanceosome and as a transcription factor with acetyltransferase and kinase activities [3,4].

In addition to the highly polymorphic ‘classical’ MHC class I and class II genes, there are other genes encoding MHC class I-type, called MHC class Ib, molecules that show little polymorphism and in some cases a restricted pattern of cellular expression [5]. They include the members of the MIC gene family encoding the MHC class I chain-related A (MICA) and MICB proteins, which are under a different regulatory control from the classical MHC class I genes and are induced in response to cellular stress [6]. MICA and MICB play a part in innate immunity as ligands for the receptor NKG2D, namely NKG2DLs, expressed on NK, gamma delta T ( $\gamma\delta$  T) and CD8 T cells and enabling these cells to kill NKG2DL-expressing targets. NKG2DLs also include the UL16 binding proteins (ULBP) [7]. HLA-E is another MHC class Ib molecule being involved in both innate and adaptive immunity with a specialized role in cell recognition by NK and of CD8 T cells [8,9]. HLA-E/peptide complexes display a dual activity. They are ligands for a multimeric receptor composed of a member of the NKG2 family (NKG2A or NKG2C) complexed with CD94 on NK and on CD8 T cells as well as for T-cell receptor of a subset of CD8 T cells [10]. CD94/NKG2A engagement inhibits the cytotoxic activity of the NK and CD8 T cells. Virally infected and cancer cells manage to escape the immune responses by the negative control of classical MHC but also by the regulation and shedding of class Ib MICA, MICB and HLA-E [11]. Modulation of MHC gene expression using drugs or immunotherapies has been proposed to reinforce the immunity against viral infections and cancers or in contrast to induce immune tolerance to treat autoimmune diseases and allergies or to avoid rejection of allotransplants [12]. Recent approaches targeting specifically MIC proteins, NKG2DLs and HLA-E or their receptors to avoid the immunosuppressive action of these MHC molecules in cancer are currently under investigations [13–15]. During inflammation and active immune responses, proinflammatory cytokines such as tumor necrosis factor (TNF) and IFN $\gamma$  are produced by immune cells and regulate the expression of genes and proteins necessary to promote adapted immune cell responses. Regulation of MHC molecules including classical class I and class II MHC (namely HLA in human) as well as non-classical MHC such as HLA-E and MICA/B on professional and non professional antigen-presenting cells such as endothelial cells (ECs) is a key process initiating both innate and adaptive immune responses.

In an attempt to identify novel immune-regulatory natural products (NPs), we recently reported on the ability of guttiferone J (1), a polyprenylated polycyclic acylphloroglucinol (PPAP) isolated from a *Garcinia virgata* herbal extract [16], to reduce inflammation as well as immunogenicity of the endothelium by inhibiting cytokine signaling pathways [17]. For a better understanding of underlying molecular mechanisms and targets, the present study reports on the isolation, identification and biological characterization of selected PPAPs, i.e., xanthochymol (2) and guttiferone F (3) from *Garcinia bancana*, which, by structural analogy, may have similar effects to guttiferone J (1) or garcinol (4). The functional activity of PPAPs 1–4 on the expression and transcriptional activation of class I and class II MHC and a set of non-classical MHC molecules such as HLA-E and MICA/B was assessed

in vitro using a cellular model consisting of human primary EC cultures treated with proinflammatory cytokines to recapitulate the features of microvascular inflammation.

## 2. Materials and Methods

### 2.1. Reagents for Biological Assays

Garcinol (**4**) was purchased from Enzo Life Sciences (Villeurbanne, France), A485 was purchased from Bio-Techne (Rennes, France) and zoledronic acid (ZA), simvastatin (Sim), Vorinostat (SAHA), Trichostatin A (TSA) and C646 (4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid) were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). Guttiferone J (**1**) has been kept in the in-house chemical library of our laboratory, which includes 139 polyphenols isolated from clusiaceous and calophyllaceous species. The extraction and purification of **1** have been previously described [16].

### 2.2. Plant Material

*Garcinia bancana* bark was collected in October 2000 around Mersing, Johor. The plant was identified by the botanist Mr. Teo Leong Eng and the voucher specimen (KL4967) was deposited at the Herbarium of the Department of Chemistry, University of Malaya, Kuala Lumpur, Malaysia.

### 2.3. Extraction and Purification

Bark powder (10 g) were successively extracted by sonication (3 h) with DCM and methanol (MeOH) to afford DCM (740 mg) and MeOH extracts (1.35 g), respectively. The DCM extract (650 mg) was then fractionated using normal phase flash chromatography on silica gel (Chromabond® flash RS 40 SiOH) from 100% cyclohexane to 70% cyclohexane/30% ethyl acetate (flow: 20 mL/min) leading to 10 sub-fractions: F1 (15.2 mg), F2 (12.2 mg), F3 (13.2 mg), F4 (18.8 mg), F5 (30.1 mg), F6 (6.5 mg), F7 (53.7 mg), F8 (27.6 mg), F9 (22.9 mg) and F10 (25.9 mg). F7 (30 mg) was separated using semipreparative HPLC (Agilent HP 1100 Series, Agilent Technologies, Les Ulis, France) on a reverse phase column (Phenomenex Luna C18, 100 Å, 250 mm × 10 mm, 5 µm), using a 50 mg/mL concentration for the injection (100 µL), with a 97% methanol + 0.1% formic acid/3% water + 0.1% formic acid system (flow: 2.8 mL/min). Fractions were collected using the Agilent Technologies 1260 Infinity G1364C fraction collector and the ChemStation for LC 3D software for automatic UV peak detection (diode array detector G13115A). This led to 8.7 mg of xanthochymol (**2**) [18] and guttiferone F (**3**) [19] as a mixture, namely **GX**. Another semi-preparative HPLC on a PFP column (Hypersil Gold PFP, 150 mm × 10 mm), using a 50 mg/mL concentration for the injection (100 µL), with a 75% methanol/25% water + 0.1% formic acid system (flow: 4.7 mL/min) yielded 2.9 mg of pure xanthochymol (**2**) and 3.6 mg of pure guttiferone F (**3**) from the remaining F7.

### 2.4. GX Analysis and 2–3 Purity

GX and PPAPs **2** and **3** were analyzed using HPLC (Agilent HP 1100 Series) on a PFP column (Hypersil Gold PFP, 150 mm × 4.6 mm), using a 1 mg/mL concentration for the injection (20 µL), with a MeOH-H<sub>2</sub>O + 0.1% formic acid gradient (55%→90% MeOH at 0–60 min, 90% MeOH 60–80 min, flow: 1 mL/min; Figure S1).

### 2.5. NMR Experiments

<sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded in methanol-d<sub>4</sub> + 0.1% trifluoroacetic acid-d on a JEOL 400 MHz YH spectrometer (Jeol Europe, Croissy-sur-Seine, France). Chemical shifts (δ<sub>H</sub> and δ<sub>C</sub>) are expressed in ppm and *J* values in Hz (Figures S2–S5).

## 2.6. Cell Culture and Treatments

Human primary vascular ECs were isolated as we previously reported [9,20] and used between passages 2 and 5. ECs were cultured in an endothelial cell basal medium (ECBM) supplemented with 5% fetal calf serum (FCS), 0.004 mL/mL ECGS/heparin, 0.1 ng/mL hEGF, 1 ng/mL hbFGF, 1 µg/mL hydrocortisone, 50 µg/mL gentamicin and 50 ng/mL amphotericin B (C-22010, PromoCell, Heidelberg, Germany). ECs isolated from different donors ( $n = 5$ ) were used in replicate experiments to ensure HLA allele diversity and avoid HLA-type-dependent effect. For activation, confluent EC monolayers were starved overnight and incubated with recombinant human IFN $\gamma$  (100 U/mL, BioTechne, Abingdon, UK) for the indicated period of time in ECBM supplemented with 2% FCS. When applicable, cells were preincubated with natural or commercial compounds (1–20 µM) or diluent alone (DMSO 1/1000) for 1 h before further incubation with TNF $\alpha$  (100 U/mL) or IFN $\gamma$  (100 U/mL) for 18 h or 48 h. Negative controls were assessed using diluent alone (DMSO 1/1000) but also structurally irrelevant biomolecules such as zoledronic acid and simvastatin.

## 2.7. Cell Immunostaining and Flow Cytometry

After treatment, cells were harvested using trypsin/EDTA before immunostaining. Cells were labeled using anti-pan HLA class I (anti-HLA-A, -B and -C; clone W6/32), anti-pan HLA class II (anti-HLA-DR, -DP, -DQ; clone L243), anti-MICA (clone AMO1; BamOmab, Tübingen, Germany), anti-HLA-E-APC (clone 3D12; Miltenyi Biotec, Paris, France) mouse IgG as primary antibodies and anti-mouse IgG + IgM (H + L)-FITC (Jackson Immunoresearch Laboratories, West Grove, PA, USA) as secondary antibodies. An isotype-matched IgG was used as the negative control. Fluorescence was measured by flow cytometry on 10,000 cells/sample using a BD FACSCanto<sup>TM</sup> II flow cytometer (Becton Dickinson, San Jose, CA, USA). Acquired data were analyzed with FlowJo software (Tree Star, Inc., Ashland, OR, USA) and depicted in histograms plotting geometric mean of fluorescence intensity (GFI) on a four-decade logarithmic scale ( $x$ -axis) versus cell number ( $y$ -axis).

## 2.8. Cellular Viability Assay

Cell toxicity was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) colorimetric assays. ECs were plated onto 96-well plates (Nunc) precoated with 1% gelatin at  $1 \times 10^4$  cells/well. Confluent EC monolayers were incubated with the tested compounds in the presence of IFN $\gamma$  (100 IU/mL) for 18 h. After treatment, cell viability was assessed by incubation with 1 mg/mL MTT (Sigma) for 4 h at 37 °C and recording the Optical Density at 550 nm. Experiments were performed in triplicates, and results are expressed as a percentage  $\pm$  SEM values. The relationship between OD and cell number was determined to be linear by the regression curve and the equation of the curve allowed us to determine the cell number for each treatment. The relative cell viability (%) was expressed as a percentage relative to the cells treated with IFN $\gamma$  and diluent (DMSO 1/1000) instead of compounds.

## 2.9. Quantitative Real-Time RT-PCR

RNA were isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), analyzed by the Caliper LabChip GX Analyzer (Perkin Elmer Inc., Wellesley, MA, USA) for quantity and quality, and treated with DNase (Ambion, Austin, TX, USA) before reverse transcription (RT). Quantitative PCRs (qPCRs) were performed using the ABI PRISM 7700 sequence detection application program (PE Applied Biosystems, Foster City, CA, USA). For quantification, means of  $C_t$  triplicates were normalized by the concomitant quantification of ribosomal protein lateral stalk subunit P0 (RPLP0, gene ID: 6175). Relative expression was calculated according to the  $2^{-\Delta\Delta C_t}$  method, as previously described [21], and using cells treated with diluent only as “calibrators” for the relative quantification. Transcript levels were quantified by real time qRT-PCR with the following predesigned TaqMan<sup>®</sup> Gene Expression Assays (FAM<sup>TM</sup> dye-labeled MGB probe), containing primers and probes, according to the manufacturer's



recommendations (Applied Biosystems, Foster City, CA, USA): Interferon Regulatory Factor 9 (IRF9 (Hs00196051\_m1)), HLA-A (Hs0740413\_g1), HLA-E (Hs03045171\_m1), MICA (Hs00792195\_m1), CIITA pIV (Hs00172106\_m1), GATA2 (Hs00231119\_m1), STAT1 (Hs01013996\_m1), HDAC3 (Hs00187320\_m1), CBP p300 (Hs00914223\_m1), CREB CBP (Hs00932878\_m1), SOCS1 (Hs00705164-s1), RPLPO (Hs99999902\_m1), MICB (Hs00792952\_m1),  $\beta$ 2-microglobulin (Hs00984230\_m1), Transporter associated with Antigen Processing 1 (TAP1(Hs00388675\_m1)), TAP Binding protein (TAPBP (Hs00542606\_m)), ULBP2 (Hs00607609\_mHl), ULBP3 (Hs00225909\_m1) and protein tyrosine phosphatase non-receptor type 11 (PTPN11 (Hs00275784\_m1)).

#### 2.10. Western Blot Analysis

Cells were lysed in RIPA buffer containing protease and phosphatase inhibitors (Sigma-Aldrich). Protein concentration was determined using the bicinchoninic acid (BCA) protein assay reagent (Pierce, Rockford, IL, USA). Cell lysates were resolved by SDS-PAGE (10%) and proteins were transferred to nitrocellulose membranes (ECL Hybond<sup>TM</sup>; Amersham, UK) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, Marne-la-Coquette, France). Then, membranes were subjected to immunoblot analysis using primary antibodies and appropriate peroxidase-conjugated secondary antibodies. Primary antibodies (dilution 1/1000) were from Cell Signaling Technology (CST, Danvers, MA, USA) and directed against: GAPDH, acetylated-CBP (K1535)/p300 (K1499), STAT1 and phosphorylated-STAT1 (Y701). Antibody-bound proteins were detected using an enhanced chemiluminescence kit (West Pico ECL, Thermo Fischer) and a luminescent image analyzer LAS-4000 (Fujifilm, Tokyo, Japan). Blot and image analysis were performed with Multi Gauge<sup>®</sup> (Fujifilm) and ImageJ<sup>®</sup> software. Results shown are representative of at least three independent experiments.

#### 2.11. Data and Statistical Analysis

Data are represented as means  $\pm$  SD for replicates experiments. Statistical analyses were performed with Graphpad Prism<sup>®</sup> Software (Graphpad Software, San Diego, CA, USA) by a Student's *t*-test, a parametric or Kruskal Wallis non-parametric analysis of variance test as appropriate. A *p* value < 0.05 (\*) was considered statistically significant. (\*\*) indicates *p* < 0.01 and (\*\*\*) *p* < 0.005.

#### 2.12. Molecular Docking

**Protein preparation:** The 3D structure of histone acetyltransferase p300 in complex with a co-crystallized inhibitor was downloaded from Protein Data Bank (PDB entry 5KJ2, rcsb.org) [22]. All implicit hydrogens (of the protein and the ligand) were added using GOLD 5.6.3 (CCDC, Cambridge, UK) [23]. Water molecules that take part in at least three hydrogen bonds with the protein and/or the ligand, at least 2 of which are with the protein, were kept. Other water molecules were deleted. Hydrogen bonds were analyzed using LigandScout 4.4 (Inteligand, Vienna, Austria) [24]. Protein treatment was done with GOLD 5.6.3. The protein structure (in the absence of the ligand) was saved as a mol2 file.

**Ligand preparation:** Three types of ligands for redocking were prepared as follows:

- Co-crystallized extracted ligand from the complex structure with no changes in conformation and configuration: the ligand (after hydrogens were added) was saved as a mol2 file without the presence of the protein and any further modification.
- Energy-minimized co-crystallized ligand extracted from the complex: the mol2 ligand structure was energetically minimized with the built-in MMFF94 function of LigandScout 4.4 and saved as another mol2 file.
- Energy-minimized reconstructed ligand: the structure of the ligand was rebuilt with ChemDraw Professional 16.0 [25], its 3D structure was then visualized from the SMILES code in the ligand-based view of LigandScout 4.4, after which the energy minimization step was carried out as described above. The fully processed ligand structure was output and saved as a mol2 file.


All test-set molecules (guttiferone J (1), xanthochymol (2), guttiferone F (3) and garcinol (4)) were downloaded from SciFinder in the sd file format. Their 2D structures were then converted into 3D, and energy minimization was carried out with LigandScout 4.4 as previously described. All output ligands were saved separately as a mol2 file.

**Molecular docking:** A rigid molecular docking procedure was carried out using GOLD 5.6.3, with all input structures (ligands and protein) in mol2 file format. The binding site comprised of all protein residues with at least one heavy atom located within 10 Å from the centroid of the co-crystallized ligand (HET code: 6TF) whose coordinates are as follows: 34.70, 9.85 and 184.79. The CHEMPLP scoring function was used to rank the output poses (Table S2). A maximal number of 10 poses were retained for each test set ligand. Post-docking interactions of all ligands with the protein were analyzed in LigandScout 4.4.

### 3. Results

#### 3.1. Phytochemical Analysis


Natural PPAPs are usually isolated from *Garcinia* (Clusiaceae) and *Hypericum* (Hypericaceae) genera [26]. For the present study, PPAPs exhibiting a similar molecular scaffold to guttiferone J (1) were required. According to the exhaustive database created by Grossman and colleagues [27], on the 774 known naturally occurring PPAPs, 75 of them share the selected skeleton (Figure 1). Among them, garcinol (4) is commercially available and was thus selected for biological assays. Moreover, to date, about 75% of PPAPs exhibiting the selected scaffold were mainly biosynthesized by *Garcinia* species. The genus *Garcinia* includes about 400 trees and shrubs growing in tropical and equatorial areas including Malaysia [28,29]. Therefore, the phytochemistry of various organs (i.e., bark, leaf and sometimes fruit) of 17 *Garcinia* species (30 batches), growing in Malaysia was investigated. The apolar NPs biosynthesized by the different organs from selected samples were extracted by dichloromethane (DCM) and extracts were analyzed using HPLC coupled to UV and mass spectrometry (LC-UV-MS<sup>2</sup>, Table S1). The DCM bark extract of *Garcinia bancana* was prone to contain PPAPs with the selected chemical scaffold as major compounds. After fractionation, a dereplication based on <sup>13</sup>C-NMR experiments confirmed the presence of isomers of garcinol (4), i.e., xanthochymol (2) and guttiferone F (3) as well as derivatives [30,31]. 2 and 3 share very similar structures and were first obtained as a mixture called GX. As previously described [32,33], the isolation of such PPAPs was challenging. Using a semipreparative HPLC, a PFP column allowed the purification of 2 and 3. Thus, the effect and mechanisms of action of PPAPs 1–4 were further investigated on endothelial cells that express a broad spectrum of MHC molecules including class I, class II, HLA-E, MICA and MICB [5].



**Figure 1.** Structure of evaluated PPAPs (1–4) and their common molecular skeleton (blue).

### 3.2. Comparative Inhibition of MHC Molecules Mediated by Guttiferones J (1) and F (3) and Xanthochymol (2)

ECs were either unstimulated or stimulated with TNF or IFN $\gamma$  in the presence of the mixture **GX** [2–3 (4:6)], **1** or diluent (DMSO) alone as negative control. Unstimulated cells were used to define baseline levels of MHC molecules. After treatment, cells were harvested and surface expression for a panel of MHC molecules including HLA class I, HLA-class II, HLA-E and MICA was measured by flow cytometry (Figure 2A). Firstly, we found that no effect of (2–3) or (1) on the basal level of MHC molecules. When compared to basal levels, TNF and IFN $\gamma$  induced a strong upregulation of MHC molecules compared to basal levels. HLA class II molecules were upregulated by IFN $\gamma$  but not by TNF. Treatment with **GX** [2–3 (4:6)] inhibited the regulation of HLA class I, HLA-Class II, HLA-E and MICA induced in response to TNF or IFN $\gamma$  on ECs. An inhibitory effect was quantitatively similar and even higher for **GX** compared to **1**. Major inhibitory effects of **GX** were observed for HLA class I and HLA-E molecules. A dose-response analysis indicated that **GX** [2–3 (4:6)] achieved a maximal inhibition of MHC molecules on the EC surface at 10  $\mu$ M (Figure 2B). Consequently, PPAPs **2** and **3** were purified. After purification, the regulatory effect of xanthochymol (**2**) and guttiferone F (**3**) on the expression of MHC proteins was further investigated. In this functional study, **2** and **3** were compared to diluent (DMSO) alone. Cells were treated with IFN $\gamma$  for 48 h and surface proteins were analyzed by flow cytometry. Figure 2C shows that **2** and **3** efficiently decreased the expression of MHC class I and class II, HLA-E and MICA at the cell surface compared to diluent and confirmed the inhibition obtained with their mixture **GX** [2–3 (4:6)]. A higher rate of MHC inhibition was achieved by **3** (up to 75% of inhibition) while inhibition by **2** was moderate (25–40% of inhibition).




**Figure 2.** Inhibitory effect of PPAPs on major histocompatibility complex (MHC) molecules expressed on endothelial cells (ECs) during exposure to proinflammatory cytokines. (A) Confluent EC monolayers



were incubated with either diluent (DMSO, 1/1000) only as a negative control, the mixture of PPAP 2 plus PPAP 3 [GX [2–3 (4:6)] or with guttiferone J (1) at 10  $\mu$ M in the presence of culture medium (no cytokine, top panel), TNF (medium panel) or IFN $\gamma$  (lower panel) for 48 h. Cells were harvested, subjected to immunolabeling with specific antibodies against HLA class I, HLA class II, HLA-E and MICA and analyzed by flow cytometry. Data are depicted as histograms of fluorescence intensity (x-axis) versus cell number (y-axis) for MHC molecules (red) and for controls (irrelevant isotype control antibodies, grey). Geometric means of fluorescence are indicated in red. (B) Dose response of inhibition mediated by the mixture of PPAPs 2 + 3 [GX, 2–3 (4:6)] before purification of the two PPAPs on the expression of HLA class I, HLA class II, HLA-E and MICA and analyzed by flow cytometry. Cells were incubated with GX (0, 0.1, 0.5, 1.0, 5.0 and 10  $\mu$ M final) in the presence of IFN $\gamma$  (100 U/mL) for 48 h before immunolabeling and flow cytometry analysis. Data are expressed as percentages calculated using values obtained with cells treated with IFN $\gamma$  plus diluent (DMSO 1/1000) as 100% of expression. (C) After purification of PPAPs, confluent EC monolayers were incubated with diluent only as a negative control, xanthochymol (2) or guttiferone F (3) at 10  $\mu$ M in the absence (–IFN $\gamma$ ) or in the presence (+IFN $\gamma$ ) of IFN $\gamma$  (100 U/mL) for 48 h. Cells were harvested, subjected to immunolabeling with specific antibodies against HLA class I, HLA class II, HLA-E and MICA and analyzed by flow cytometry. Data are depicted as histograms of fluorescence intensity (x-axis) versus cell number (y-axis) for MHC molecules (red) and for controls (irrelevant isotype control antibodies, grey). Geometric means of fluorescence are indicated in red. Results are representative data from 3 independent experiments.

### 3.3. Guttiferones J (1) and F (3) and Xanthochymol (2) Are Novel Inhibitors of HAT CBP/p300 Activity, Which Impair IFN $\gamma$ Signaling and Ultimately MHC Expression through the Inhibition of STAT1 Transcriptional Activities

To decipher the mechanisms involved in the inhibition of MHC molecules mediated by PPAPs, we employed quantitative real time RT-PCR (qRT-PCR) to quantify cellular mRNA levels and we focused on the IFN $\gamma$  signaling that mediate the regulation of most MHC molecules. In these experiments, cells were treated with diluent alone, GX [2–3 (4:6)], 1 or garcinol (4) in the presence of IFN $\gamma$  for 18 h before cell lysis and RNA isolation. For comparison, cells were also treated with a statin (simvastatin) or with zoledronic acid (ZA), two compounds previously reported to downregulate MHC antigens [17,34]. For this study, we focused on the two MHC molecules involved in both innate and adaptive immunity, namely HLA-E and MICA. Firstly, qRT-PCR showed that IFN $\gamma$  efficiently upregulated HLA-E and downregulated MICA transcript levels as we previously reported [9,35] (Figure 3A). Further, our results confirmed that both GX [2–3 (4:6)] and 4 reduced significantly mRNA levels in IFN $\gamma$ -treated ECs while 1 had no effect on MICA mRNA. GX [2–3 (4:6)], 1 and 4 also decrease mRNA levels for STAT1 and SOCS1, two signaling proteins, which mediate IFN $\gamma$  signaling pathway in the cells indicating that GX [2–3 (4:6)], 1 and 4 are potent inhibitors of IFN $\gamma$  signaling. GX [2–3 (4:6)], 1 and 4 also provide an effective decrease in mRNA for the transcription factor CIITA pIV a master regulator of MHC molecules [4]. Since the PPAP garcinol (4) was previously reported as an inhibitor of histone acetyltransferase (HAT) [36] mRNA levels for HAT p300 CBP, CREB CBP and histone deacetylase HDAC3 were quantified. We found that GX [2–3 (4:6)], 1 and 4 achieved a diminution in HATs p300 and CBP and in a minor extent in HDAC3 mRNA levels 18 h post-treatment. Interestingly, our study shows no regulatory activity, in our conditions, for simvastatin and ZA on mediators of IFN $\gamma$  signaling and on CIITA expression. Consistent with these findings no regulation for HLA-E or MICA was found at the protein level (Figure S6). However, simvastatin and ZA also achieved efficient inhibition of HAT p300 and CBP.



**Figure 3.** (A) Inhibitory effect of PPAPs on the IFN $\gamma$  signaling pathway and HAT p300/HDAC3. Confluent EC monolayers were incubated with compounds GX [2–3 (4:6)], guttiferone J (1) garcinol (4), simvastatine (Simva) or zoledronic acid (ZA) at 10  $\mu$ M with IFN $\gamma$  (100 U/mL) or diluent alone (DMSO, 1/1000) for 18 h. Cells were harvested for RNA isolation and qRT-PCR for the following transcripts: HLA-E, MICA, STAT1, SOCS1, CIITA pIV, CREB/CBP, p300 and HDAC3. Results shown are means of triplicate experiments, data were normalized using a housekeeping gene (RPLPO) and expressed as  $2^{-\Delta\Delta C_t}$  using cells treated with diluent alone (DMSO, 1/1000) as reference. (B) Dose-dependent effect of PPAPs 2–4, HAT (A485, C646) and HDAC3 (SAHA) inhibitors on cell viability. ECs were cultured for 18 h with compounds (1–20  $\mu$ M) or diluent in the presence of IFN $\gamma$  (100 U/mL) for 18 h. Cell viability was assessed in triplicates using MTT staining and expressed as relative percentages calculated using diluent as reference (100%), \*  $p < 0.05$ , \*\*  $p < 0.01$  versus diluent.

To explore further the properties of PPAPs, the following experiments were conducted using purified xanthochymol (2) and guttiferone F (3) in comparison to garcinol (4) and to two synthetic inhibitors of HAT CBP/p300 (C646 and A485) and HDAC (SAHA). Firstly, we used a cell viability assay to measure the cytotoxic effect PPAPs at concentrations from 1 to 20  $\mu$ M. These experiments show that PPAPs 2–4 and HAT or HDAC inhibitors achieved no significant cell toxicity at a concentration equal or below 10  $\mu$ M (Figure 3B). Consequently, the following experiments were conducted using a concentration of 10  $\mu$ M for all compounds.

The effect of purified PPAPs 2–4 was further investigated by qRT-PCR for the analysis of MHC, MHC-like (MICA/B), MHC-related molecules ( $\beta$ 2-microglobulin, TAP1 and Tapasin) and proteins involved in their regulation in response to IFN $\gamma$  such as STAT1, SOCS1, CIITA and IRF9 (Figure 4A). Firstly, we found that, in our experimental conditions, IFN $\gamma$  increased significantly the expression of HLA class I, HLA-E,  $\beta$ 2M, TAP1, Tapasin, STAT1, SOCS1, CIITA and IRF9. In contrast, IFN $\gamma$  had no effect on MICB, GATA2 and SHP2 and decreased significantly the NKG2D ligands MICA,

ULBP2 and ULBP3. In these conditions, PPAPs 2–4 significantly inhibited the regulatory effect of IFN $\gamma$  by decreasing the transcript level for HLA class I, HLA-E,  $\beta$ 2M and tapasin. TAP1 was selectively inhibited by 4 while 2–3 had no effect. PPAPs 2–4 further decreased MICA and MICB levels but had an opposite effect on ULBP2 and no effect on ULBP3. A significant inhibitory effect of STAT1 and SOCS1, which reflects a loss of IFN $\gamma$  signal, was observed for 2 and 3 confirming the data obtained with the mixture GX before their purification. Next, target genes of STAT1, coding for factors involved in the transcriptional activation of MHC and HLA-E, CIITA, GATA2 and IRF9 were quantified. CIITA and GATA2 mRNA levels were dramatically reduced in the presence of PPAPs 2–4 consistent with an upstream dysfunction of IFN $\gamma$  signaling. IRF9 was lightly increased by 2 but reduced by 4, A485 and SAHA. No effect was found for Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) a protein tyrosine phosphatase involved in signal transduction by regulating several canonical pathways (MAPK and PI3K). Using Western blot experiments, we observed that PPAPs 2–4 reduce significantly the phosphorylation of STAT1 (Y701) and also reduce the acetylation of CBP (K1535)/p300 (K1499) suggesting hypoacetylation of CBP/p300 (Figure 4B,C). Inhibition of HAT acetylation was also achieved using A485. Together these data may suggest that, similar to garcinol (4), PPAPs 1–3 display an inhibition of HAT activities that subsequently impairs IFN $\gamma$  signaling and transcriptional activity required for MHC regulation. Finally, we used flow cytometry to assess whether inhibition of HAT in EC cultures may affect MHC protein expression. To this aim, cells were treated with potent inhibitors of either HAT (C646) or HDAC (SAHA, TSA) during stimulation with IFN $\gamma$ . Our findings revealed that blocking HAT using C646 dramatically impairs the expression of HLA class I and HLA-E (Figure 4D). In contrast, blocking HDACs has no effect.





Figure 4. Cont.




**Figure 4.** (A) Effect of PPAPs 2–4, on MHC and MHC-related protein expression, transcriptional regulation. Confluent EC monolayers were incubated with diluent alone (DMSO, 1/1000) or with diluent, PPAPs 2–4, HAT (A485, C646), HDAC3 (SAHA) inhibitors and with IFN $\gamma$  (100 U/mL) for 18 h. Cells were harvested for RNA isolation and qRT-PCR for the following transcripts: HLA class I, HLA-E, MICA, MICB, ULBP2, ULBP3,  $\beta$ 2 microglobulin ( $\beta$ 2M), TAP1, Tapasin, STAT1, SOCS1, CIITA pIV, GATA2, IRF9 and SHP2. Results shown are means of triplicate experiments, data were normalized using a housekeeping gene (RPLPO) and expressed as  $2^{-\Delta\Delta C_t}$  using cells treated with diluent alone (DMSO, 1/1000) as reference. (B) Representative Western blots for total STAT1, phosphorylated STAT1, acetylated p300/CBP and GAPDH in ECs cultured for 6 h in the presence of compounds (10  $\mu$ M) and IFN $\gamma$  (100 U/mL). Doublets observed for STAT1 correspond to  $\alpha$  and  $\beta$  STAT1 subunits. Results are representative data from 3 independent experiments. (C) Quantification of immunoblots for phosphorylated STAT1, acetylated p300/CBP from 3 independent experiments after normalization to GAPDH levels. (D) Effect of HAT and HDAC3 inhibitors on MHC expression. Confluent ECs monolayers were cultured for 48 h with HAT (C646) or HDAC (SAHA or TSA) inhibitors at 10  $\mu$ M and with IFN $\gamma$  (100 U/mL) or diluent alone (DMSO, 1/1000). Cells were harvested, subjected to immunolabeling with specific antibodies against HLA class I or HLA-E and analyzed by flow cytometry. Data shown are representative histograms showing log of fluorescence intensity vs. cell number for the MHC molecules HLA class I and HLA-E (red) compared to negative controls (irrelevant isotype control antibodies, grey). Geometric means of fluorescence are indicated in red, \*  $p < 0.05$ , \*\*  $p < 0.01$  versus diluent plus IFN $\gamma$ .

### 3.4. Molecular Docking in the Binding Site of Histone Acetyltransferase p300

Biologically evaluated PPAPs 1–4 were also successively docked in the selective catalytic site of the histone acetyltransferase p300 previously described for A-485 [37]. Previously, the best redocked poses into the binding site (heavy atoms only) of the original structure and its energy-minimized conformation, as well as the rebuilt structure (created according to our protocol described in Materials and Methods) of the native ligand (HET code: 6TF, namely A-485) obtained with GOLD 5.6.3 deviated 0.45 Å, 0.73 Å and 1.43 Å from the true crystal pose deposited in the Protein Data Bank, respectively, denoted that the docking procedure managed to correctly pose the ligand and could be employed for further investigation (Figure S7). It was observed that the key interactions between the native ligand and several amino acid residues of the binding site were preserved in all redocked poses. Such interactions include a hydrogen bond between the A-485 ligand's methyl-urea moiety and the backbone carbonyl of Gln1455, as well as another hydrogen bond that involves the carbonyl group substituted at the C-4' position on the oxazolidinedione structure of A-485 and the hydroxyl group of



Ser1400. Interestingly, the latter hydrogen bond was also observed in all best docked poses of PPAPs 1–4. As depicted in Figure 5, for garcinol (4) and guttiferone F (3), it was the carbonyl substituent at the C-4 position of the bicyclo [3.3.1] nonane structure that participated in a hydrogen bond with Ser1400; while for guttiferone J (1) and xanthochymol (2), the carbonyl groups at C-9 (of the same cyclic scaffold) and at C-1' were involved, respectively. As this amino acid is located at the center of the binding site, its strong interaction with the ligands could help to stabilize the protein–ligand complexes and is expected to impair the biological activity of the protein in a similar manner to that observed with the native ligand A-485.



**Figure 5.** Docking poses for (A) garcinol (4), (B) guttiferone F (3), (C) guttiferone J (1) and (D) xanthochymol (2) in the binding site of histone acetyltransferase p300. Red and green arrows represent hydrogen bond acceptors and donors, respectively, and yellow spheres show the hydrophobic contacts between the ligands and the protein.

#### 4. Discussion

IFN $\gamma$  is a central effector of cell-mediated immunity. Its immunomodulatory effects include enhancement of antigen processing and presentation through the regulation of MHC molecules on immune and on endothelial cells. In the present study, we demonstrated that, in the presence of IFN $\gamma$ , the inhibition of MHC molecules on cell surface by the PPAPs 1, 2, 3 and the GX mixture [2–3 (4:6)] was associated with reduced transcript levels for MHC molecules. This suggests that the inhibitory action of PPAPs may result from a regulation of the transcriptional activation. To decipher the transcriptional processes involved, we investigated the impact of PPAPs with a selected scaffold on the canonical IFN $\gamma$ /Jak/STAT signaling pathway, which initiates the transcriptional regulation of MHC molecules.



Mechanistically, IFN $\gamma$  transmits a signal through the IFN $\gamma$  receptor (IFNGR), composed of IFNGR1 and IFNGR2 subunits. In canonical IFN $\gamma$ -Jak-STAT1 signaling (reviewed in [38]), ligand engagement of the IFNGR leads to activation of receptor-associated kinases Jak1 and Jak2 via the phosphorylation of a receptor tyrosine residue (Y440) that serves as a docking site for STAT1, present in a latent state in the cytoplasm. STAT1 is then activated by phosphorylation of tyrosine 701 (Y701), translocates to the nucleus, binds to a regulatory DNA element termed gamma-activated sequence (GAS) and stimulates transcription of STAT1 target genes [39,40]. STAT1 binds to DNA as a dimer composed of two STAT1 subunits ( $\alpha$  and  $\beta$ ). Transcriptional activity of STAT1 is repressed by the negative regulators of signaling SOCS1, a key suppressor of IFN $\gamma$  activities [41]. STAT1 undergoes cycles of activation–inactivation that are coupled with cytoplasmic–nuclear shuttling and regulated by post-translational modifications, including dephosphorylation of Y701 and acetylation of lysine residues K410 and K413 in the DNA binding domain (DBD) [42–44].

Here, we quantified the mRNA coding for transcription factors (STAT1), regulators (SOCS1) and coactivators (CIITA, GATA2 and IRF9) induced by IFN $\gamma$  signaling and implicated in MHC transcription. We found that, concurrently to their effects on MHC mRNA levels, PPAPs 1–4 also significantly diminished mRNA for STAT1 and SOCS1, reflecting a globally reduced activity of the IFN $\gamma$  signaling pathway consistent with a reduced MHC mRNA and protein expression. A decrease in the phosphorylation level of STAT1 molecules was further observed in the presence of PPAPs by Western blot, consistently with a reduced activity of the IFN $\gamma$  signaling pathway. Phosphorylated STAT1 dimerized and moved rapidly into the nucleus, where it bound to the GAS element of the promoters to initiate transcription of IFN $\gamma$  primary response genes. In the MHC, these included *TAP1*, *Hsp70/90* (*HSPA1*), *tapasin* (*TAPBP*) and *CIITA* [45–47], which are required for subsequent activation of the HLA genes. *GATA2*, *CIITA* and *tapasin* were also found inhibited by PPAPs 2–4 while *TAP1* was only inhibited by 4. However, *SH2P2*, which operates downstream of EGFR, dephosphorylated and inhibited *p*-STAT1 and was not inhibited by PPAPs 2–4 [48]. The inhibitions observed at the mRNA level for several of these intracellular factors remains to be evaluated at the protein level.

Histone hyperacetylation of MHC genes occurs rapidly after IFN $\gamma$  treatment and is followed by transcription [49]. Therefore, we sought to determine whether PPAPs 2–4 might act initially through changes on acetylation/deacetylation shuttling as previously reported for garcinol (4) [50,51]. Lysine acetylation is a reversible post-translational modification that plays a crucial role in regulating protein function, chromatin structure and gene expression. Histone hyperacetylation by HATs is associated with activation of transcription, whereas HDACs is associated with transcriptional repression. Site-specific acetylation of a growing number of non-histone proteins has been shown to regulate their activity, localization, specific interactions and stability/degradation. Consequently, protein acetylation is a key target in drug design for several diseases. It was recently showed that garcinol (4) dose-dependently decreased the protein levels of p300/CBP HATs [52]. Thus, to characterize the biological functions of PPAPs 2 and 3, we investigated their effect on the p300/CBP family including p300 and CREB-binding protein (CBP). CBP and p300 display dual activity as coactivators for a number of transcription factors that function as scaffolds for assembling multiprotein complexes and as enzymes that catalyze acetylation of lysine [52]. CBP and p300 HAT activity can be inhibited by NPs, such as curcumin, epigallocatechin-3-gallate and garcinol (4) [37]. Synthetic compounds were also identified including C646, a competitive p300 inhibitor, and A485 a CBP and p300 inhibitor with lower IC<sub>50</sub> and less off-target effects [37].

Here, we indicate that xanthochymol (2), guttiferone F (3) and garcinol (4) decrease CBP/p300 HAT mRNA levels, suggesting that functionally both 2 and 3 display CBP/p300 HAT inhibition as 4. In a coherent way, molecular docking experiments confirmed that PPAPs 1–4 might bind at the active site of p300 HAT where the native ligand A-485 is getting docked. In contrast, no significant effect was found for these compounds on the HDAC3 mRNA steady state level. Thus, since STAT1 is a non-histone target of CBP/p300 our data suggest that a reduced STAT1 mRNA level may result from the PPAPs inhibition of STAT1 acetylation/phosphorylation shuttling. Consistent with this

hypothesis, our biochemical analysis showed that PPAPs efficiently decrease STAT1 phosphorylation to the same extent as A485, a specific CBP/p300 HAT inhibitor [37]. Western blots also revealed a hypoacetylation of HAT CBP/p300, a feature of HAT loss of activity [53], in the presence of PPAPs that sustains an inhibitory effect of PPAPs on HAT CBP/p300. A485 that we used as a positive control also conducted a significant hypoacetylation of CBP/p300 in our conditions. Together these findings suggest that decreased MHC expression in the presence of 2, 3 and 4 results firstly from the post-translational inhibition of acetylation/phosphorylation of STAT1 by inhibiting HAT CBP/p300 activity that subsequently represses STAT1 transcription. Measurement of HLA-E mRNA and protein in the presence of commercial HAT inhibitors C646 and A485 further confirmed that blocking HAT CBP/p300 during IFN $\gamma$  stimulation efficiently prevents the expression of HLA-E. STAT1 is required for the transcription of numerous target genes [40], several being involved in IFN $\gamma$ -dependent regulation of MHC such as CIITA, IRF9, GATA2, TAP1 and Tapasin. In cultured ECs treated with IFN $\gamma$  we found that 2, 3 and 4 strongly impaired mRNA for CIITA pIV and GATA2, both being transactivators for HLA-E transcription, a key MHC molecule in ECs. A similar effect was achieved in the presence of the HAT inhibitor A485 and to a lesser extend of C646.

Our findings indicates that, by interfering with IFN $\gamma$  signaling, PPAPs 1–4 efficiently decreased the expression of a non-classical MHC (HLA-E) and MHC-related molecules that include MICA, MICB but also proteins implicated in the peptide transport (TAP1), loading (tapasin) and MHC assembly ( $\beta$ 2M). Concerning the decrease in HLA-E expression it can be speculated that decreased expression in the presence of PPAPs could be due directly to a specific inhibition of *HLA-E* gene transcription or could be the indirect consequence of MHC class Ia transcription inhibition leading to a lack of nonapeptides from MHC class I required for HLA-E protein expression and stability. It is also possible that both mechanisms occur. Functional differences between the two major HLA-E allelic variants (HLA-E \*01:01 and HLA-E \*01:03) related to HLA-E stabilization and peptide presentation have been reported [54]. Similar, MICA allelic variants also affect MICA protein function and stability [15]. Therefore, it could be of interest to further investigate the effects of PPAPs using cells homozygous for various HLA-E or MIC alleles to specifically address this point. Moreover, future experiments exploring the effect of PPAPs on cancer cells with dysregulated levels of HLA-E, MICA/B and MHC are also needed.

## 5. Conclusions

We identified guttiferone J (1), xanthochymol (2) and guttiferone F (3) as novel and potent inhibitors of HAT CBP/p300 activity. This is a common property shared with garcinol (4). Inhibition of HAT CBP/p300 activity mediated by 2 and 3 deeply impairs IFN $\gamma$  signaling and ultimately MHC expression through the inhibition of STAT1 transcriptional activities probably as a result of STAT1 acetylation/phosphorylation dysregulation. Decrease in STAT1 level reduces the transcription of STAT1-dependent transactivators such as CIITA and GATA2 required for efficient transcription of MHC molecules. Overall, these findings provide new insights on the epigenetic control of MHC and propose PPAPs as useful scaffolds for improved drug design or probes targeting HAT.

**Supplementary Materials:** The following are available online at <http://www.mdpi.com/2218-273X/10/9/1266/s1>, Figure S1: HPLC-UV chromatogram of GX from *Garcinia bancana* (bark) dichloromethanic extract, Figure S2:  $^1\text{H}$ -NMR spectrum of xanthochymol 2, Figure S3:  $^{13}\text{C}$ -NMR spectrum of xanthochymol 2, Figure S4:  $^1\text{H}$ -NMR spectrum of guttiferone F 3, Figure S5:  $^{13}\text{C}$ -NMR spectrum of guttiferone F 3, Figure S6: Superimposes of the original structure A-485 and its energy-minimized conformation as well as the rebuilt structure in the binding site of histone acetyltransferase p300, Figure S7: Superimposes of the original structure A-485 and its energy-minimized conformation as well as the rebuilt structure in the binding site of histone acetyltransferase p300. Table S1. *Garcinia* species from Malaysia (Name, voucher number and available organs) and data on their phytochemistry. Table S2. ChemPLP scores for the top 10 poses in docking experiments.

**Author Contributions:** This article is based on the results obtained by C.C., supervised by S.D. and B.C., during her master's degree. C.C., N.G. and B.C. performed biological experiments. C.R. and S.T.L. made extraction and preliminary analyses on Malaysian *Garcinia* species. S.T.L., supervised by K.A., extracted and fractionated *Garcinia bancana* bark extract. The phytochemical study of *Garcinia bancana* was undertaken by C.C. and A.B., directed by S.D. and P.R. C.P.D. and S.D. made molecular docking experiments. This work was supervised by S.D. and B.C.

S.D. and B.C. prepared the figures and tables and wrote the manuscript together. All authors discussed the results from the experiments and commented on the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by la Region Pays de la Loire (grant “Paris Scientifique, HYPROTEC”), the “Grégory Lemarchal” and “Vaincre la Mucoviscidose” non-profit organizations (grant number RF20190502487) and l’Institut de Recherche en Santé Respiratoire des Pays de la Loire (grant CYTOP). AB and CR gratefully acknowledge the Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation (MESRI, France) for PhD grants. STL and KA (PANASIA project) are grateful for the support of Le ministère de l’Europe et des Affaires Étrangères (MEAE, France) for providing an International Travel Grant.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Janeway, C.A. How the immune system protects the host from infection. *Microbes Infect.* **2001**, *3*, 1167–1171. [[CrossRef](#)]
2. Chaplin, D.D. Overview of the immune response. *J. Allergy Clin. Immunol.* **2010**, *125*, S3–S23. [[CrossRef](#)] [[PubMed](#)]
3. Castro, F.; Cardoso, A.P.; Goncalves, R.M.; Serre, K.; Oliveira, M.J. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. *Front. Immunol.* **2018**, *9*, 847. [[CrossRef](#)] [[PubMed](#)]
4. Devaiah, B.N.; Singer, D.S. CIITA and Its Dual Roles in MHC Gene Transcription. *Front. Immunol.* **2013**, *4*, 476. [[CrossRef](#)] [[PubMed](#)]
5. Gavlovsky, P.-J.; Tonnerre, P.; Guitton, C.; Charreau, B. Expression of MHC class I-related molecules MICA, HLA-E and EPCR shape endothelial cells with unique functions in innate and adaptive immunity. *Hum. Immunol.* **2016**, *77*, 1084–1091. [[CrossRef](#)]
6. González, S.; Groh, V.; Spies, T. Immunobiology of Human NKG2D and Its Ligands. *Curr. Top. Microbiol. Immunol.* **2006**, *298*, 121–138. [[CrossRef](#)]
7. Nausch, N.; Cerwenka, A. NKG2D ligands in tumor immunity. *Oncogene* **2008**, *27*, 5944–5958. [[CrossRef](#)]
8. Jia, Y.; Pang, C.; Zhao, K.; Jiang, J.; Zhang, T.; Peng, J.; Sun, P.; Qian, Y. Garcinol Suppresses IL-1 $\beta$ -Induced Chondrocyte Inflammation and Osteoarthritis via Inhibition of the NF- $\kappa$ B Signaling Pathway. *Inflammation* **2019**, *42*, 1754–1766. [[CrossRef](#)]
9. Coupel, S.; Moreau, A.; Hamidou, M.; Horejsi, V.; Soulillou, J.P.; Charreau, B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. *Blood* **2007**, *109*, 2806–2814. [[CrossRef](#)] [[PubMed](#)]
10. Jouand, N.; Bressollette-Bodin, C.; Gerard, N.; Giral, M.; Guerif, P.; Rodallec, A.; Oger, R.; Parrot, T.; Allard, M.; Cesbron-Gautier, A.; et al. HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition. *PLoS Pathog.* **2018**, *14*, e1007041. [[CrossRef](#)] [[PubMed](#)]
11. Morvan, M.; Lanier, L.L. NK cells and cancer: You can teach innate cells new tricks. *Nat. Rev. Cancer* **2015**, *16*, 7–19. [[CrossRef](#)] [[PubMed](#)]
12. Bluestone, J.A. Mechanisms of tolerance. *Immunol. Rev.* **2011**, *241*, 5–19. [[CrossRef](#)] [[PubMed](#)]
13. Schmiedel, D.; Mandelboim, O. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. *Front. Immunol.* **2018**, *9*, 2040. [[CrossRef](#)] [[PubMed](#)]
14. Van Hall, T.; Andre, P.; Horowitz, A.; Ruan, D.F.; Borst, L.; Zerbib, R.; Narni-Mancinelli, E.; van der Burg, S.H.; Vivier, E. Monalizumab: Inhibiting the novel immune checkpoint NKG2A. *J. Immunother. Cancer* **2019**, *7*, 263. [[CrossRef](#)] [[PubMed](#)]
15. Zingoni, A.; Molfetta, R.; Fionda, C.; Soriani, A.; Paolini, R.; Cippitelli, M.; Cerboni, C.; Santoni, A. NKG2D and Its Ligands: “One for All, All for One”. *Front. Immunol.* **2018**, *9*, 476. [[CrossRef](#)]
16. Merza, J.; Mallet, S.; Litaudon, M.; Dumontet, V.; Seraphin, D.; Richomme, P. New cytotoxic guttiferone analogues from *Garcinia virgata* from New Caledonia. *Planta Med.* **2006**, *72*, 87–89.
17. Rouger, C.; Pagie, S.; Derbré, S.; Le Ray, A.-M.; Richomme, P.; Charreau, B. Prenylated Polyphenols from Clusiaceae and Calophyllaceae with Immunomodulatory Activity on Endothelial Cells. *PLoS ONE* **2016**, *11*, e0167361. [[CrossRef](#)]

18. Iinuma, M.; Tosa, H.; Tanaka, T.; Asai, F.; Kobayashi, Y.; Shimano, R.; Miyauchi, K.-I. Antibacterial Activity of Xanthones from Guttiferae Plants against Methicillin-resistant *Staphylococcus aureus*. *J. Pharm. Pharmacol.* **1996**, *48*, 861–865. [CrossRef]
19. Fuller, R.W.; Blunt, J.W.; Boswell, J.L.; Cardellina, J.H.; Boyd, M.R. Guttiferone F, the First Prenylated Benzophenone from *Allanblackia stuhlmannii*. *J. Nat. Prod.* **1999**, *62*, 130–132. [CrossRef]
20. Tonnerre, P.; Gerard, N.; Chatelais, M.; Charreau, B. MICA Gene Polymorphism in Kidney Allografts and Possible Impact of Functionally Relevant Variants. *Transplant. Proc.* **2010**, *42*, 4318–4321. [CrossRef]
21. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) Method. *Methods* **2001**, *25*, 402–408. [CrossRef] [PubMed]
22. Berman, H.M.; Battistuz, T.; Bhat, T.N.; Bluhm, W.F.; Bourne, P.E.; Burkhardt, K.; Feng, Z.; Gilliland, G.L.; Iype, L.; Jain, S.; et al. The Protein Data Bank. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **2002**, *58*, 899–907. [CrossRef] [PubMed]
23. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. *Proteins: Struct. Funct. Bioinform.* **2003**, *52*, 609–623. [CrossRef] [PubMed]
24. Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters. *J. Chem. Inf. Model.* **2005**, *36*, 160–169. [CrossRef]
25. Chatterjee, A.; Yasmin, T.; Bagchi, D.; Stohs, S.J. The bactericidal effects of *Lactobacillus acidophilus*, garcinol and Protargin compared to clarithromycin, on *Helicobacter pylori*. *Mol. Cell. Biochem.* **2003**, *243*, 29–35. [CrossRef]
26. Al-Qahtani, K.; Jabeen, B.; Sekirnik, R.; Riaz, N.; Claridge, T.D.W.; Schofield, C.J.; McCullagh, J.S. The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves. *Phytochemistry* **2015**, *117*, 456–461. [CrossRef]
27. Yang, X.-W.; Grossman, R.B.; Xu, G. Research Progress of Polycyclic Polyprenylated Acylphloroglucinols. *Chem. Rev.* **2018**, *118*, 3508–3558. [CrossRef]
28. KewScience, Plants of the World Online. *Garcinia* L. 2020. Available online: <http://plantsoftheworldonline.org/taxon/urn:lsid:ipni.org:names:19345-1> (accessed on 6 January 2020).
29. Tropicos, Missouri Botanical Garden. 2020. Available online: <https://www.tropicos.org> (accessed on 6 January 2020).
30. Bruguere, A.; Derbre, S.; Coste, C.; Le Bot, M.; Siegler, B.; Leong, S.T.; Sulaiman, S.N.; Awang, K.; Richomme, P. (13)C-NMR dereplication of *Garcinia* extracts: Predicted chemical shifts as reliable databases. *Fitoterapia* **2018**, *131*, 59–64. [CrossRef]
31. Hubert, J.; Nuzillard, J.M.; Purson, S.; Hamzaoui, M.; Borie, N.; Reynaud, R.; Renault, J.H. Identification of natural metabolites in mixture: A pattern recognition strategy based on (13)C NMR. *Anal. Chem.* **2014**, *86*, 2955–2962. [CrossRef]
32. Li, J.; Gao, R.; Zhao, D.; Huang, X.; Chen, Y.; Gan, F.; Liu, H.; Yang, G. Separation and preparation of xanthochymol and guttiferone E by high performance liquid chromatography and high speed counter-current chromatography combined with silver nitrate coordination reaction. *J. Chromatogr. A* **2017**, *1511*, 143–148. [CrossRef]
33. Roux, D.; Hadi, H.A.; Thoret, S.; Guenard, D.; Thoison, O.; Pais, M.; Sevenet, T. Structure-activity relationship of polyisoprenyl benzophenones from *Garcinia pyrifera* on the tubulin/microtubule system. *J. Nat. Prod.* **2000**, *63*, 1070–1076. [CrossRef] [PubMed]
34. Coupel, S.; Leboeuf, F.; Boulday, G.; Soulillou, J.-P.; Charreau, B. RhoA Activation Mediates Phosphatidylinositol 3-Kinase-Dependent Proliferation of Human Vascular Endothelial Cells: An Alloimmune Mechanism of Chronic Allograft Nephropathy. *J. Am. Soc. Nephrol.* **2004**, *15*, 2429–2439. [CrossRef] [PubMed]
35. Chauveau, A.; Tonnerre, P.; Pabois, A.; Gavlovsky, P.J.; Chatelais, M.; Coupel, S.; Charreau, B. Endothelial cell activation and proliferation modulate NKG2D activity by regulating MICA expression and shedding. *J. Innate Immun.* **2014**, *6*, 89–104. [CrossRef] [PubMed]
36. Balasubramanyam, K.; Altaf, M.; Varier, R.A.; Swaminathan, V.; Ravindran, A.; Sadhale, P.P.; Kundu, T.K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. *J. Biol. Chem.* **2004**, *279*, 33716–33726. [CrossRef] [PubMed]
37. Lasko, L.M.; Jakob, C.G.; Edalji, R.P.; Qiu, W.; Montgomery, D.; Digiammarino, E.L.; Hansen, T.M.; Risi, R.M.; Frey, R. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature* **2017**, *550*, 128–132. [CrossRef]



38. Schindler, C.; Plumlee, C. Interferons open the JAK–STAT pathway. *Semin. Cell Dev. Biol.* **2008**, *19*, 311–318. [[CrossRef](#)]
39. Hu, X.; Ivashkiv, L.B. Cross-regulation of signaling pathways by interferon-gamma: Implications for immune responses and autoimmune diseases. *Immunity* **2009**, *31*, 539–550. [[CrossRef](#)]
40. Satoh, J.; Tabunoki, H. A Comprehensive Profile of ChIP-Seq-Based STAT1 Target Genes Suggests the Complexity of STAT1-Mediated Gene Regulatory Mechanisms. *Gene Regul. Syst. Biol.* **2013**, *7*, 41–56. [[CrossRef](#)]
41. O’Shea, J.J.; Murray, P.J. Cytokine signaling modules in inflammatory responses. *Immunity* **2008**, *28*, 477–487. [[CrossRef](#)]
42. Thompson, P.R.; Wang, D.; Wang, L.; Fulco, M.; Pediconi, N.; Zhang, D.; An, W.; Ge, Q.; Roeder, R.G.; Wong, J.; et al. Regulation of the p300 HAT domain via a novel activation loop. *Nat. Struct. Mol. Biol.* **2004**, *11*, 308–315. [[CrossRef](#)]
43. Kramer, O.H.; Heinzel, T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. *Mol. Cell. Endocrinol.* **2010**, *315*, 40–48. [[CrossRef](#)] [[PubMed](#)]
44. Zhuang, S. Regulation of STAT signaling by acetylation. *Cell. Signal.* **2013**, *25*, 1924–1931. [[CrossRef](#)] [[PubMed](#)]
45. Min, W.; Pober, J.S.; Johnson, D.R. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: The rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. *J. Immunol.* **1996**, *156*, 3174–3183.
46. Herberg, J.A.; Sgouros, J.; Jones, T.; Copeman, J.; Humphray, S.J.; Sheer, D.; Cresswell, P.; Beck, S.; Trowsdale, J. Genomic analysis of the Tapasin gene, located close to the TAP loci in the MHC. *Eur. J. Immunol.* **1998**, *28*, 459–467. [[CrossRef](#)]
47. Van den Elsen, P.J.; Holling, T.M.; Kuipers, H.F.; van der Stoep, N. Transcriptional regulation of antigen presentation. *Curr. Opin. Immunol.* **2004**, *16*, 67–75. [[CrossRef](#)] [[PubMed](#)]
48. Leibowitz, M.S.; Srivastava, R.M.; Andrade Filho, P.A.; Egloff, A.M.; Wang, L.; Seethala, R.R.; Ferrone, S.; Ferris, R.L. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2013**, *19*, 798–808. [[CrossRef](#)]
49. Spilianakis, C.; Kretsovali, A.; Agaloti, T.; Makatounakis, T.; Thanos, D.; Papamatheakis, J. CIITA regulates transcription onset via Ser5-phosphorylation of RNA Pol II. *EMBO J.* **2003**, *22*, 5125–5136. [[CrossRef](#)]
50. Oike, T.; Ogiwara, H.; Torikai, K.; Nakano, T.; Yokota, J.; Kohno, T. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. *Int. J. Radiat. Oncol. Biol. Phys.* **2012**, *84*, 815–821. [[CrossRef](#)]
51. Wang, B.; Lin, L.; Ai, Q.; Zeng, T.; Ge, P.; Zhang, L. HAT inhibitor, garcinol, exacerbates lipopolysaccharide-induced inflammation in vitro and in vivo. *Mol. Med. Rep.* **2016**, *13*, 5290–5296. [[CrossRef](#)] [[PubMed](#)]
52. Wang, J.; Wu, M.; Zheng, D.; Zhang, H.; Lv, Y.; Zhang, L.; Tan, H.S.; Zhou, H.; Lao, Y.Z.; Xu, H.X. Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-beta1 signaling pathways. *Acta Pharmacol. Sin.* **2020**, *41*, 82–92. [[CrossRef](#)] [[PubMed](#)]
53. Chan, H.M.; La Thangue, N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. *J. Cell Sci.* **2001**, *114*, 2363–2373. [[PubMed](#)]
54. Celik, A.A.; Kraemer, T.; Huyton, T.; Blasczyk, R.; Bade-Döding, C. The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch. *Immunogenetics* **2016**, *68*, 29–41. [[CrossRef](#)] [[PubMed](#)]

